Inhibition of Wnt signaling pathway or absence of TSP1 decreases cellular <i>T</i>. <i>cruzi</i> infection. by Ashutosh Arun (2574559)

Plasma from ATTR individuals presents a higher proteolytic activity. by Gonçalo da Costa (198731)

Stapler liver resection leads to a decreased IL-6 response compared to CUSA transection. by Christoph Schwarz (238062)

Th2 cytokines and IgE were decreased in G-1-treated C57BL/6 mice compared to non-treated mice. by Masamichi Itoga (706167)

Developmental delay of <i>rpS13/+</i> animals is not due to a decrease in ribosome numbers or reduced translation rates. by Lisa Patricia Deliu (13570709)

Decreased presence of tubulin-GFP at axonal MTs in a pulse chase experiment suggests changes in MT replenishment with age. by Pilar Okenve-Ramos (18150546)

<i>Pw1</i> deletion does not result in significant decrease in oxytocin production and release. by Anne-Lyse Denizot (3170142)

Competition localization increases with growth rate or the distances between colonies, and decreases with the resource diffusion constant. by Jeremy M. Chacón (8259792)

CyaA decreases the capacity of TLR-stimulated DCs to present soluble antigen to CD4⁺ T cells. by Irena Adkins (173166)

Downregulation of LGR4 decreases ARPE-19 cell migration. by Qiang Hou (495704)

LRP deficiency in MΦ's results in normal IFN-γ response but decreased IL-4. by Roman Covarrubias (602292)

KPn infection decreases the level of surface exposed phosphatidylserine (PS) and reduces efferocytosis of infected neutrophils. by Christopher N. Jondle (5807657)

Blocking VIP-signaling decreased inflammation and necrosis in the liver and lung of mCMV-infected mice. by Jian-Ming Li (319425)

HAART does not affect CTLA-4 expression, but significantly decreases CD39 expression in Tregs. by Pietro Presicce (144163)

HAART decreased enhanced expression of cell cycling markers in Tregs from HIV-infected subjects. by Pietro Presicce (144163)

List of Included studies. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

<i>patDp</i>/+ mice display decreased exploratory activity in the open field test. by Kota Tamada (235174)